Farletuzumab
- Generic Name
- Farletuzumab
- Drug Type
- Biotech
- CAS Number
- 896723-44-7
- Unique Ingredient Identifier
- 2O09BG0OWA
- Background
Farletuzumab (MORAb-003) is a fully humanized monoclonal antibody against the folate receptor alpha, for the potential treatment of epithelial ovarian cancer.
- Indication
Investigated for use/treatment in ovarian cancer.
Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy
Phase 2
Completed
- Conditions
- Ovarian CancerPeritoneal NeoplasmsFallopian Tube Cancer
- Interventions
- Drug: Chemo Plus Far
- First Posted Date
- 2006-04-26
- Last Posted Date
- 2015-09-09
- Lead Sponsor
- Morphotek
- Target Recruit Count
- 58
- Registration Number
- NCT00318370
- Locations
- 🇺🇸
The Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸Hematology and Oncology Specialists, LLC, Metarie, Louisiana, United States
🇺🇸The Center for Cancer and Hematologic Disease, Cherry Hill, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath